Hong Kong Breast Cancer Study

NCT ID: NCT02889458

Last Updated: 2023-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

7000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-09-30

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction: With population ageing and increasing Westernization breast cancer continues to be important health conditions among women in Hong Kong. Greater collaborative research efforts are needed to examine the questions about population screening for breast cancer, the aetiology of such lesions and outcomes of breast cancer during survivorship period. There is a lack of locally-relevant models for assessing breast cancer risk. Contribution of novel genetic factors to breast cancer, identification of the key and functional alleles in gene regions associated with risk of breast cancer as well as gene-environment interaction, requires further investigation in Chinese population. Prognostic research studies in the West may not be readily applicable to the Chinese population.

Objectives: We aim to investigate the aetiology and outcomes of breast cancer in local Chinese by using case-control and cohort study design in the health care setting in Hong Kong. We aim to examine potential risk factors/biomarkers (both traditional and novel), and to build infrastructure and biobank for breast cancer surveillance. We will follow up cases prospectively as a survivor cohort.

Methods: A hospital-based case-control study and a prospective survivor cohort study will be conducted. Consecutive incident breast cancer and DCIS cases (n=3,501) within a 36-month period in Hong Kong were recruited from public hospitals, private hospitals and private practices; and controls were selected by frequency-matching on factors such as age and hospital/clinic setting, whenever possible. Cases will be prospectively followed up over a 10-year period, and data collection will occur at baseline (within 24 weeks of diagnosis), 3, 5 and 10 years following baseline assessment. Biologic samples (including both blood, and tumour and normal breast tissue samples from the cases, and blood samples from the controls) will be collected for later genetic and molecular study including WGS, GWAS, gene-environment interaction and molecular functional studies. Depending on availability of pathology samples and resources, additional studies such as tissue microarray block production will be considered and performed in future. Data will be analysed by traditional regression, EWAS and genetic association methods, whenever relevant.

Public Health Implications: The repository of clinical, radiological and biological materials assembled through this case-control study will serve as a common, publicly accessible platform for subsequent functional analysis and scientific interrogation. The case-control findings would offer an improved understanding to the state of the science on aetiology of breast cancer in Chinese women. In the genomics analysis, potential refined classification of breast tumours may enhance our understanding, detection and follow-up of such lesions, as well as enable us to have more informed targeted and personalized treatment selection for our women population. The cohort study findings are important for developing an effective strategy for the improvement of overall survival and quality of life for the cancer survivors in Chinese population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Ductal Carcinoma In Situ

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Inclusion Criteria

* Female
* aged 18 or above
* Chinese
* Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)
* Able to speak Cantonese
* Newly diagnosed with breast cancer or DCIS in 24 weeks

Exclusion Criteria

\- Undergoing treatment for any non-breast cancer

Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected.

Not Provided

Intervention Type OTHER

Control

Inclusion Criteria

* Female
* aged 18 or above
* Chinese
* Usually residing in Hong Kong
* Able to speak Cantonese

Exclusion Criteria

\- History of any cancer

Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected.

Not Provided

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Not Provided

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female
* aged 18 or above
* Chinese
* Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)
* Able to speak Cantonese
* Newly diagnosed with breast cancer or DCIS in 24 weeks


* Female
* aged 18 or above
* Chinese
* Usually residing in Hong Kong
* Able to speak Cantonese

Exclusion Criteria

* Undergoing treatment for any non-breast cancer


\- History of any cancer
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Food and Health Bureau, Hong Kong

OTHER_GOV

Sponsor Role collaborator

The University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Professor Gabriel Matthew Leung

Dean, Li Ka Shing Faculty of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gabriel M Leung, MD

Role: PRINCIPAL_INVESTIGATOR

Li Ka Shing Faculty of Medicine, The University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Baptist Hospital

Hong Kong, , Hong Kong

Site Status

Caritas Medical Centre

Hong Kong, , Hong Kong

Site Status

Evangel Hospital

Hong Kong, , Hong Kong

Site Status

Grantham Hospital

Hong Kong, , Hong Kong

Site Status

HK Sanatorium and Hospital

Hong Kong, , Hong Kong

Site Status

Kwong Wah Hospital

Hong Kong, , Hong Kong

Site Status

North District Hospital

Hong Kong, , Hong Kong

Site Status

Pamela Youde Nethersole Eastern Hospital

Hong Kong, , Hong Kong

Site Status

Pok Oi Hospital

Hong Kong, , Hong Kong

Site Status

Prince of Wales Hospital

Hong Kong, , Hong Kong

Site Status

Princess Margaret Hospital

Hong Kong, , Hong Kong

Site Status

Queen Elizabeth Hospital

Hong Kong, , Hong Kong

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

Ruttonjee Hospital

Hong Kong, , Hong Kong

Site Status

St. Paul's Hospital

Hong Kong, , Hong Kong

Site Status

St. Teresa's Hospital

Hong Kong, , Hong Kong

Site Status

Tseng Kwan O Hospital

Hong Kong, , Hong Kong

Site Status

Tuen Mun Hospital

Hong Kong, , Hong Kong

Site Status

Union Hospital

Hong Kong, , Hong Kong

Site Status

United Christian Hospital

Hong Kong, , Hong Kong

Site Status

Yan Chai Hospital

Hong Kong, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BrCA.risk.001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Ghana Breast Health Study
NCT01661023 COMPLETED